-+ 0.00%
-+ 0.00%
-+ 0.00%

Acumen plans presentation of Phase 2 sabirnetug trial baseline data at CTAD

PUBT·10/22/2026 11:31:52
Listen to the news
Acumen plans presentation of Phase 2 sabirnetug trial baseline data at CTAD
  • Acumen Pharmaceuticals will present three posters on its Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer’s disease.
  • Presentations are scheduled for Nov. 16-17, 2026, at the Clinical Trials on Alzheimer’s Disease conference in Boston, running Nov. 16-19.
  • The posters will cover preliminary participant baseline characteristics, treatment expectations and motivations, and care partners’ experiences.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220730PRIMZONEFULLFEED9850829) on October 22, 2026, and is solely responsible for the information contained therein.